Sanofi (SNY)
Sanofi Asset Utilization
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About Asset Utilization
The asset utilization ratio calculates the total revenue earned for every dollar of assets a company owns. This ratio indicates a company's efficiency in using its assets.
For example, with an asset utilization ratio of 52%, a company earned $.52 for each dollar of assets held by the company.
Learn More
You may also be interested in these SNY related companies
SNY News
Amylin (AMLN) Shares Jump as Bids Due Today, Sanofi (SNY), Merck (MRK) Said to Make First-Round Bids
May 25, 2:01PM Street Insider
May 25, 2:01PM Street Insider
Mylan (MYL) Unit Launches Generic Version of Sanofi-Aventis' (SNY) Plavix
May 17, 1:42PM Street Insider
May 17, 1:42PM Street Insider
SPDR S&P 500 ETF and Bank of America Among Most Active Stocks in Pre-Market Today on the NYSE
May 17, 9:36AM Minyanville
May 17, 9:36AM Minyanville
$SNY why all the call interest today? Todays most active Options Sanofi 99.6% calls wow... http://stks.co/3qwq
about 10 days ago by justfurkids
about 10 days ago by justfurkids
The Drama Continues At $AMLN: Takeover Still Likely. $BMY $LLY $SNY http://stks.co/3prL
about 11 days ago by abubnic
about 11 days ago by abubnic
5 Top International Dividend Stocks http://stks.co/3kyJ $SNY $CRH $ABB $SID $CS
about 17 days ago by myplaniq
about 17 days ago by myplaniq
$SNY - Closed out at the Initial Stop of $35.62 - http://stks.co/3kS9
about 17 days ago by TraderFoxxx
about 17 days ago by TraderFoxxx
Sanofi's (SNY) Genzyme Gets EMA, FDA Approval for Second Suite at Irish Plant
May 03, 7:37AM Street Insider
May 03, 7:37AM Street Insider
Genzyme Announces Regulatory Approvals of Expanded Waterford, Ireland Manufacturing Plant
May 03, 1:00AM Business Wire
May 03, 1:00AM Business Wire
Sanofi iBGStar® Blood Glucose Monitoring System Now Available in the U.S.
May 02, 8:00AM PR Newswire
May 02, 8:00AM PR Newswire
Sanofi-Aventis's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Apr 27, 5:45PM Seeking Alpha
Apr 27, 5:45PM Seeking Alpha
Emerging market push and Genzyme acquisition paying dividends for $SNY 9.9% sales growth significantly outperforming rivals $GSK and $AZN
about 29 days ago by sld1986
about 29 days ago by sld1986
Call $SNY "Stk revalues due to change in biz mix, geo. mix, and lack of patent exposure past '12" http://stks.co/3QzB $PFE $MRK $GSK
about 36 days ago by SumZero
about 36 days ago by SumZero
Quick Pitch: Long on $AZN Target Price: $62 http://stks.co/3Jz7 $SNY $NVS "Best downside protection among Pharma large caps"
about 44 days ago by SumZero
about 44 days ago by SumZero
$AAPL 3D camera patent in works. Who will get the nod as supplier? Either/or/both? $OVTI $SNY >> http://stks.co/3CBy
about 54 days ago by IncrementalWealth
about 54 days ago by IncrementalWealth
Trade Signal-New $SNY -BTO @ 38.08 Limit w/35.62 Stop on the Wkly Chart w/.5N @ Risk http://chart.ly/pygmwen
about 75 days ago by TraderFoxxx
about 75 days ago by TraderFoxxx
News related to $SNY, currently +0.1% since open: 'FDA links once-promising pain drugs to bone decay' http://stks.co/2jWz
about 79 days ago by TradeBot
about 79 days ago by TradeBot
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SNY | 34.31 | +0.08 | +0.23% | 92.01B |
| SNPS | 29.89 | +0.04 | +0.13% | 4.358B |
| SNP | 90.85 | +0.14 | +0.15% | 86.14B |
| SNMX | 2.33 | -0.04 | -1.69% | 92.66M |
| SNH | 20.78 | -0.03 | -0.14% | 3.380B |
| SNE | 13.30 | -0.46 | -3.34% | 13.35B |
| SNCR | 17.85 | -0.05 | -0.28% | 687.58M |
| SMTC | 24.08 | +0.38 | +1.60% | 1.575B |
| SMSC | 36.55 | -0.02 | -0.05% | 812.51M |
| SMS | 10.81 | -1.05 | -8.85% | 2.225B |
